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Abstract 
Neurofibromatosis type 1 (NF1) is a multisystem disease with autosomal dominant 
inheritance and complete penetrance diagnosed by clinical findings. Cutaneous 
neurofibromas are present in almost all adult patients in the dermis, epidermis or along 
the peripheral nerves. Plexiform neurofibromas are subcutaneous or deep lesions 
involving nerve plexuses or roots. Neurofibromas can degenerate into malignant tumors, 
with important prognostic implications. NF1 shows a broad clinic variability even within 
a single family. Exceptions are cases reporting the in-frame microdeletion  
c.2970_2972delAAT, presenting with the typical pigmentary features of NF1, but no 
cutaneous or plexiform neurofibromas. We report a patient with a de novo 
c.2970_2972delAAT mutation who had few café-au-lait spots, only 2 of which measured 
>15 mm, axillary and submammary freckling, a flat angioma extending over the neck, 
arm and trunk, a high arched palate, micrognathia, macrocephaly, pes cavus and 
scoliosis. There was complete absence of observable cutaneous neurofibromas as well as 
external plexiform neurofibromas. She had had epileptic seizures since childhood; 
however, a diagnosis of NF1 had not been confirmed until she was 38, partly due to the 
paucity of characteristic cutaneous stigmata. We confirm the association of the 
c.2970_2972delAAT mutation in NF1 with a particular clinical phenotype, especially with 
lack of detectable neurofibromas. For an appropriate management of patients and family 
counseling, molecular study of the NF1 gene should be considered in patients not  
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fulfilling NIH criteria when other features suggestive of NF1 are present. In the absence 
of neurofibromas, starting NF1 testing with the screening of exon 17 may be worthwhile. 
Introduction 
Neurofibromatosis type 1 (NF1; MIM 162200) is a multisystem disease with autosomal 
dominant inheritance and complete penetrance. The diagnosis of NF1 is made based on 
clinical findings: café-au-lait (CAL) spots, skinfold freckling, neurofibromas and Lisch 
nodules, which are present in most patients after puberty and may be associated with 
other manifestations. Cutaneous neurofibromas are present in almost all patients by age 
20 in the dermis, epidermis or along the peripheral nerves [1]. Plexiform neurofibromas 
are subcutaneous lesions with ill-defined margins that can also be located deeply within 
the body, involving nerve plexuses and spinal roots. Although molecular genetic analysis 
is available for NF1 and is useful for the diagnostic confirmation, the clinical variability – 
sometimes extreme even within a single family – together with the lack of genotype to 
phenotype correlation limits the usefulness of routine genetic testing. One exception is 
the complete gene deletion causing severer symptoms [2]. More recently, a 3-bp in-frame 
deletion c.2970_2972delAAT in exon 17 was reported to correlate with pigmentary NF1 
features but with no cutaneous or plexiform neurofibromas [3]. 
Case Report 
We report a patient that had been followed up for a long time in Paediatrics, Neurology and 
Psychiatry departments with behavioural problems, dyslexia and epilepsy since childhood. She had had 
a mild psychomotor delay. She had been able to hold her head up at 7 months, to sit unaided at 17 
months and to walk at 21 months. She had said the first words at 23 months and at the age of 3 she had 
shown mild behavioural problems. She had been delayed at school, with learning difficulties and 
dyslexia. Since age 2 she had been suffering from epileptic seizures, combining partial complex and 
generalized (atonic, tonic-clonic) seizures. 
At the age of 38 years, she presented the following signs: 6 CAL spots of 10–20 mm (2 of them >15 
mm), a few other CAL spots with smaller dimensions, axillary and submammary freckling, a flat 
angioma extending over neck, arm and trunk (fig. 1), high arched palate, micrognathia, macrocephaly, 
pes cavus and scoliosis. Nerve conduction studies were normal. There was complete absence of 
observable cutaneous neurofibromas as well as external plexiform neurofibromas. Complete bone 
radiology and cardiologic evaluation were normal. No Lisch nodules were seen on eye examination. The 
patient’s mother had multiple moles and freckles, but no other symptoms suggestive of NF1, and 
neither did any of the patient’s sisters or her children. Specifically, the presence of optic gliomas was 
ruled out through ophthalmological, neuroimaging and neurophysiologic examinations. Brain and 
spinal cord MRI studies performed at 23, 30, 34, and 37 years of age were all normal. Axial, sagittal and 
coronal MRI images were acquired with a 1.5-T machine using T1-, proton density-, and T2-weighted 
sequences, as well as inversion-recovery sequences. 
The patient had a normal 46XX karyotype. In order to screen for small rearrangements associated 
with cranial dysmorphism and learning delay, the Cytogenetics Whole Genome 2.7M Array 
(Affymetrix) was performed, ruling out a 22q11 deletion as well as alterations in 10p13, 4q35, 17p13 
and 18q21. Genetic testing of the NF1 gene in a peripheral blood sample from this patient showed the 
presence of the in-frame mutation c.2970_2972delAAT, p.Met992del (NM_000267.1) in exon 17 
(fig. 2). This mutation was absent in all the first-degree relatives studied, and haplotype segregation 
indicated that it arose de novo on the paternal chromosome (fig. 2).  
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Discussion 
Most NF1 mutations are truncating, and missense mutations and small deletions or 
insertions are infrequent [4]. Other sporadic cases with the same microdeletion have been 
reported and its recurrence may be facilitated by the deletion of an aat looping out of a 
hairpin structure [3]. Our data, together with previous evidence, support the 
pathogenicity of the c.2970_2972delAAT mutation. It showed complete co-segregation 
with the disease in reported families, was not found in healthy individuals and was absent 
in the parents of sporadic cases [3]. Understanding the molecular mechanisms by which 
this mutation prevents neurofibroma formation may open up avenues for therapeutic 
intervention; it does not seem to affect NF1 splicing [3]. 
The clinical characteristics of our patient are reminiscent of other cases with the 
c.2970_2972delAAT mutation: CAL spots and freckles but complete absence of skin and 
plexiform neurofibromas. She did show, however, features reportedly less frequent in 
patients with this mutation compared to NF1 cohorts, such as macrocephaly and learning 
problems [3, 5]. 
This case confirms that the mutation c.2970_2972delAAT in NF1 is associated with a 
particular phenotype, especially with the absence of detectable neurofibromas. Although a 
complete lack of subcutaneous and plexiform neurofibromas is difficult to ascertain, an 
absence or reduced frequency of these lesions seem also the case in other patients with 
this mutation [3]. Since the burden of neurofibromas is associated with the risk of 
malignant nerve sheath tumours, this genotype-phenotype correlation is very useful for 
follow-up planning and genetic counselling. Strictly speaking, our patient did not fulfil 
any of the NIH criteria for NF1 [6, 7] except skinfold freckling. The number of CAL 
lesions was low, only 2 of them measuring >15 mm. However, a reduction in the number 
of CAL macules with age has been reported [8]. Thus, attention must be paid to the 
possibility that some NF1 mutations, such as the c.2970_2972delAAT and possibly other 
in-frame mutations, may present with an attenuated phenotype so that a proper NF1 
diagnosis cannot be formulated according to the current diagnostic criteria. 
Modifications of these criteria may be necessary to include the finding of a known 
pathogenic mutation. The NF1-like Legius syndrome caused by mutations in SPRED1 
must also be considered in the differential diagnosis of cases with CAL spots without 
neurofibromas. In these cases, however, other typical NF1 features are generally also 
absent [9, 10]. 
The symptom combination in this patient, particularly the low burden of cutaneous 
manifestations, delayed the diagnosis for many years; she had 3 children before genetic 
confirmation was achieved. Given the importance of diagnostic confirmation not only for 
appropriate management of patients but also for family counselling [11], the molecular 
study of the NF1 gene should be considered in children with developmental delay, 
epilepsy, behavioural and learning disability, as well as in adults without NIH criteria but 
with other features in the spectrum of NF1. In the absence of neurofibromas, it may be 
worthwhile that the patient be screened first for the presence of the c.2970_2972delAAT 
mutation in exon 17.  
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Fig. 1. Detail of the patient’s back (a) and abdomen (b) showing a cervical-thoracic flat angioma, few 
CAL spots and absence of neurofibromas. 
 
 
 
Fig. 2. Pedigree of the family showing that the mutation emerged de novo on the paternal chromosome; 
markers are indicated from telomere to centromere. Presence and absence of the mutation are indicated 
with plus and minus, respectively. Inset A fragment of the sequence of exon 17 showing the trace 
overlap caused by the c.2970_2972delAAT deletion in NF1. 
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